



Table S1. Panel of SNPs investigated.

Gene	Rs Code	Polymorphism	Amino acid	Genotype	Functional effects
<b>Transporters</b>					
<b>ABCB1/MDR1</b>	rs1128503 rs1045642	C1236T C3435T	Gly412Gly Ile1815=	<b>T allele leads to lower activity</b>	Decreased
<b>ABBC1/MRP1</b>	rs45511401	G671V-G>T	Gly671Val		
<b>ABCB1</b>	rs4148738	G>A	Intron	A allele leads to increased	Dabigatran concentration
<b>ABCC2/MRP2</b>	rs8187710 rs17222723	G4544A T3563A	Cys1515Tyr Val1188Glu	A allele leads to lower activity	Decreased
<b>ABCC2 24C&gt;T</b>	rs717620	C5116T	Promoter	T allele leads to lower expression	Lower expression
<b>ABCG2</b>	rs2231142	C421A	Gln141Lys	A allele leads to lower expression	Lower expression
<b>SLC15A2-L350F</b>	rs2257212	C>T	Leu350Phe	-	-
<b>SLCO1B1</b>	rs4363657 rs4149056	T521C T>C	Intron Val174Ala	C allele leads to lower activity	Decreased
<b>5HTT-LPR</b>		Repeat region	Promoter	S allele leads to lower transcription	
<b>CYP</b>					
<b>CYP1A2*1C</b>	rs2069514	G3860A	None	A allele leads to lower activity	Decreased
<b>CYP1A2*1F</b>	rs762551	C163A	Intron	A allele leads to increased inducibility	Increased
<b>CYP2C19*17</b>	rs12248560	C806T	Upstream	Heterozygous	Increased
<b>CYP2C19*10</b>	rs6413438	C680T	Pro227Leu	T/A/G alleles leads to lower activity	Decreased
<b>CYP2C19*2</b>	rs4244285	G681A	Pro227=		
<b>CYP2C19*3</b>	rs4986893	G636A	Trp212Ter		
<b>CYP2C19*4</b>	rs28399504	A5026G	Met1Val	Homozygous	Increased
<b>CYP2C19*5</b>	rs56337013	C1297T	Arg433Trp		
<b>CYP2C19*7</b>	rs72558186	T24319A	Splice Donor		
<b>CYP2C9*2</b>	rs1799853	C430T	Cys144Arg	T/C allele leads to lower activity	Decreased
<b>CYP2C9*3</b>	rs1057910	A1075C	Ile359Leu		
<b>CYP2D6*2</b>	rs16947	C2850T	Arg296Cys	Homozygous	Increased
<b>CYP2D6*XN</b>	-	-	Amplification	-	
<b>CYP2D6*10</b>	rs1065852	C100T	Pro34Ser	<b>Heterozygous</b>	<b>Decreased</b>
<b>CYP2D6*17</b>	rs28371706	C1023T	Thr107Ile		
<b>CYP2D6*6</b>	rs5030655	1707delT	Trp152fs		
<b>CYP2D6*20</b>	rs72549354	insG	Leu213fs		
<b>CYP2D6*5</b>	-	Deletion	Stop codon	-	Decreased
<b>CYP2D6*38</b>	rs72549351	delGACT	Thr272fs		

<b>CYP2D6*29</b>	rs61736512	G1659A	Val136Met	A allele leads to lower activity	Decreased
<b>CYP2D6*2A</b>	rs1080985	C1584G	Upstream	Homozygous	Decreased
<b>CYP2D6*3</b>	rs35742686	2549delA	Arg259fs		
<b>CYP2D6*4</b>	rs3892097	G1846A	Acceptor		
<b>CYP2D6*41</b>	rs28371725	G2988A	Intron		
<b>CYP2D6*7</b>	rs5030867	A2935C	His324Pro		
<b>CYP2D6*9</b>	rs5030656	2615-2617delAAG	Inframe del.		
<b>CYP3A4*1B</b>	rs2740574	A392G	Upstream	Homozygous	Decreased
<b>CYP3A4*22</b>	rs35599367	C15389T	Intron	G alleles lead to increased activity	Increased
<b>CYP3A5*3</b>	rs776746	A6986AG	Acceptor	Heterozygous	Decreased
<b>CYP1A1</b>	rs1048943	T>C	Ile462Val	C allele leads to increased activity	Increased
<b>CYP2B6</b>	rs2279343 rs3745274 rs3211371 rs28399499	A785G G516T C1459T T 983C	Lys262Arg Gln172His Arg487Cys Ile328Thr	G/T allele leads to lower activity	Decreased
<b>CYP2A6</b>	rs28399433 rs1801272	A48C T>A		C/A allele leads to lower expression	Decreased
<b>CYP2C8*2</b>	rs11572103	A805T	Ile269Phe	-	-
<b>CYP2C8*4</b>	rs1058930	C792G	Ile264Met	C allele leads to lower activity	Decreased
<b>Other drug metabolizing enzymes</b>					
<b>TPMT*2</b>	rs1800462	C>G	Ala80Pro	C allele leads to lower activity	Decreased
<b>TPMT*3B</b>	rs1800460	G460A	Ala154Thr	Heterozygous	Decreased/Inactive
<b>TPMT*3C</b>	rs1142345	A719G	Tyr240Cys		
<b>UGT1A1*28</b>	rs8175347	(TA)(n) repeat sequence	TATA box	6/7 repeat	Decreased
<b>UGT2B17</b>		Deletion		Heterozygous	Decreased
<b>DPYD</b>	rs3918290 rs67376798	IVS14+1G>A A2846T	Splice donor Asp949Val	Heterozygous Homozygous	Decreased
<b>DPYD*6</b>	rs1801160	G>A	Val732Ile	A allele leads to lower activity	Decrease
<b>DPYD*9A</b>	rs1801265	T>C	Cys29Arg	-	-
<b>DPY</b>	rs2297595	A166G	Initiator Co-don	-	-
<b>COMT</b>	rs4680 rs4633	G>A C>T	Val158Met His62His	A/T alleles lead to lower activity	Decreased

COMT	rs4818	C>G	Leu136Leu	G alleles lead to increased activity	Increased
MTHFR	rs1801133 rs1801131	C677T A1298C	Ala222Val Glu429Ala	T/C alleles lead to lower activity	Decreased
TYMS	rs45445694	TSER*2/TSER*3	28 bp repeat in enhancer region	Increased transcription	Increased
	rs2853542 rs34743033	TSER*3R G/C	second repeat of 3R allele	Reduced transcription	Decreased
	rs151264360 rs869066439	1494del6b	I/D of TTAAAG sequence on the 3'-UTR	TYMS mRNA instability	Decreased
NAT1*14B	rs4986782	G560A	Arg187Gln	A allele leads to lower activity	Decreased
NAT1*15B	rs5030839	C599T	Stop Codon	-	Inactive
NAT1*17B	rs56379106	C190T	Arg64Trp	C alleles lead to lower activity	Decreased
NAT1*22B	rs56172717	A752T	Asp251Val	T alleles lead to lower activity	Decreased
NAT2*3	rs1801280	T341C	Ile114Thr	C/A alleles lead to lower activity	Decreased
NAT2*6	rs1799930	G590A	Arg197Gln		
NAT2*7	rs1799931	G857A	Gly286Glu		
UMPS	rs1801019	G213A G>C	Gly213Asp Gly213Ala	-	-
CBS	rs234706	C699T	-	Allele T associated with increased risk of ammonia and sulphite detoxification defects	
Receptors					
DRD2/ANKK1-Q713K	rs1800497	C957T		Heterozygous	Reduced dopamine binding sites
DRD2-141-insC/delC	rs1799732	insC/delC	Upstream	Heterozygous	Reduced receptor expression
DRD2-S311C	rs1801028	C932G	Ser311Cys	Heterozygous	Decreased affinity for dopamine
DRD3-S9G	rs6280	A25G	Gly9Ser	Homozygous	Normal
HTR2A	rs6314	C1354T	His452Ty	Heterozygous	-
	rs7997012	A>G	Intron	Homozygous	-
	rs6311	G1438A	Upstream	Homozygous	-
HTR2C	rs6318	G68C	Cys23Ser	Homozygous	Increased cardiovascular events
OPRM1	rs1799971	A118G	Asn40Asp	Heterozygous	More pain
Oxidation reduction enzymes					

<b>GSTP1</b>	rs1695	A313G	Ile105Val	C allele leads to lower activity	Decreased
<b>GSTM1 GSTT1</b>		Deletion		Heterozygous	Inactive
<b>DNA repair enzymes</b>					
<b>ERCC1</b>	rs3212986 rs11615	C8092A T19007C	3 Prime UTR Asn118=	-	-
<b>XRCC1</b>	rs25487	G28152A	Gln399Arg	Heterozygous	Decreased
<b>Lipid metabolism</b>					
<b>APOA1</b>	rs1799837	G75A		Protective against cardiovascular event	
<b>APOB1</b>	rs5742904	G10580A	Arg3500Gln	Heterozygous	Hypercholesterolemia
<b>CETP</b>	rs1532624	C>A	Intron	-	-
<b>HMGCR</b>	rs3761740 rs5908	C911A A>G	Upstream tra. Ile585Val	-	-
<b>PON1</b>	rs662 rs705379	A575G C108T	Gln192Arg Upstream	G/T alleles lead to lower activity	Decreased
<b>Coagulation enzymes</b>					
<b>VKORC</b>	rs9923231	G1639A	Upstream	A/T alleles lead to less coagulating capacity	Decreased
	rs9934438	C1173T	Intron		
<b>CES1</b>	rs2244613 rs8192935	A>C C>T	Intron	C allele leads to decreased Dabigatran concentration	
<b>F II</b>	rs1799963	G20210A	3 Prime UTR	-	-
<b>PAI</b>	rs1799889	4G/5G	Upstream	Heterozygous	Increased risk of thrombotic events
<b>F V</b>	rs6025	G1691A	Arg506Gln	A allele Increased	risk of thrombotic events
<b>β-fibrinogen</b>	rs1800790	G455A	-	-	-
<b>FattoreXIII</b>	rs5985	G>T	Val135Leu	-	-

Abbreviation: ABCB1, ATP binding cassette subfamily B member 1; ABCC1, ATP Binding Cassette Subfamily C Member 1; MRP1, Multidrug resistance-associated protein 1; ABCC2, ATP Binding Cassette Subfamily C Member 2; MRP2, Multidrug resistance-associated protein 2; ABCG2, ATP-binding cassette sub-family G membro 2; SLC15A2, Solute Carrier Family 15 Member 2; SLC01B1, solute carrier organic anion transporter family member 1B1; 5-HTTLPR, serotonin-transporter-linked polymorphic region; CYP1A2, Cytochrome P450 Family 1 Subfamily A Member 2; CYP2C19, cytochrome P450 family 2 subfamily C member 19; CYP2D6 Cytochrome P450 family 2 subfamily D member 6; CYP3A4, Cytochrome P450 family 3 subfamily A member 4; CYP3A5, Cytochrome P450 family 3 subfamily A member 5; CYP1A1 Cytochrome P450 family 1 subfamily A member 1; CYP2B6 Cytochrome P450 family 2 subfamily B member 6; CYP2C8, Cytochrome P450 family 2 subfamily C member 8; TPMT, Thiopurine methyltransferase; UGT1A1, uridine-diphosphoglucuronate glucuronosyltransferase; DPYD, dihydropyrimidinase; COMT, catechol O-methyltransferase; TSER, syn-thase enhancer region; MTHFR, methylenetetrahydrofolate reductase; TYMS, thymidylate synthase; NAT1, Arylamine N-acetyltransferase 1; NAT2, Arylamine N-acetyltransferase 2; UMP5, Uridine Monophosphate Synthetase; DRD2, do-pamine receptor D2; ANKK1, Ankyrin repeat and kinase domain containing 1; HTR2A, 5-Hydroxytryptamine Receptor 2A; HTR2C, 5-Hydroxytryptamine Receptor 2C; OPRM1, Opioid Receptor Mu 1; GSTP1, Glutathione S-Transferase P1; GSTM1, glutathione S-transferase Mu 1; GSTT1, Glutathione S-Transferase Theta 1; ERCC1, Excision Repair 1, Endonu-lease Non-Catalytic Subunit; XRCC1, X-ray repair cross complementing protein 1; APOA1, Apolipoprotein A1; APOB1, Apolipoprotein B1; CETP, Cholesteryl ester transfer protein; HMGCR, 3-Hydroxy-3-Methylglutaryl-CoA Re-ductase; PON1, paraoxonase/arylesterase 1; VKORC, Vitamin K epoxide Reductase Complex; CES1 Carboxylic ester hydrolase; F II, coagulation factor II; PAI, Plasminogen Activator Inhibitor; F V, coagulation factor V; CBS, cystathionine beta-synthase; F XIII, coagulation factor XIII;